Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
← catalyst calendarSponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With PSI CRO.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
24actual
Sites
7
Countries
Bulgaria, Germany, Italy +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-24 | actual | When the study began enrolling |
| Primary completion | 2026-05-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-21 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemophilia A
Intervention
- Drug: Efanesoctocog alfa — also filed as BIVV001, Altuvoct, Altuviiio
Primary outcome
what the primary-completion date above is the date OFHalf-life (t½) of efanesoctocog alfa, damactocog alfa pegol and turoctocog alfa pegol after a single i.v. injection
measured up to 7 days and 14 days after the administration of the respective drugs.
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed